A Phase II Trial of CVAD/Verapamil/Quinine for Treatment of Non-Hodgkin's Lymphoma
Publication Information Expand/Collapse
PMid: PMID29370458 | PMC number: PMC5963502
Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials
PMid: PMID24633940 | PMC number: PMC4137041
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma. a Southwest Oncology Group study
Infusional therapy with first generation chemosensitizers (CS) results in increased toxicity without improved benefit in untreated lymphoma.